CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.

JCO Global Oncology is a premier open-access journal published by Lippincott Williams & Wilkins, dedicated to the dissemination of high-quality research in the fields of cancer research and oncology. Since its inception in 2020, this journal has rapidly established itself as a vital resource for researchers, healthcare professionals, and students, holding a distinguished position in the Q2 category for both Cancer Research and Oncology based on the latest metrics. With an impressive Scopus rank of #61 out of 636 in General Medicine, the journal is recognized for its rigorous peer-reviewed articles and cutting-edge insights into oncological science. The open-access model ensures that vital research is readily available to a global audience, fostering collaborative advancements in the fight against cancer. JCO Global Oncology explores a broad range of topics and encourages submissions that contribute to the understanding, prevention, and treatment of various malignancies. With its substantial impact and ongoing contributions to the field, it stands as a promising platform for advancing oncological discourse and knowledge.

The World Journal of Oncology, published by ELMER PRESS INC, is a vibrant platform for disseminating groundbreaking research and advancements in the field of oncology. With its ISSN 1920-4531 and E-ISSN 1920-454X, this journal is dedicated to publishing high-quality studies that enhance our understanding of cancer and its treatment. The journal is recognized for its significant contributions, evidenced by its Q2 classification in both Cancer Research and Oncology categories in 2023, and accolades such as a Scopus rank of #126/404 in Medicine _ Oncology. Catering to the needs of researchers, professionals, and students, the World Journal of Oncology offers an essential resource for the latest scientific insights and clinical practices, ensuring the global oncology community remains informed and engaged. The journal operates under a selective publication model, maintaining rigor in peer review while facilitating knowledge sharing across converged years from 2014 to 2016 and 2020 to 2024, further establishing its importance in the ongoing fight against cancer.

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.